Frontotemporal dementia and pharmacologic interventions.
Frontotemporal lobar degeneration is comprised of three syndromes: frontotemporal dementia (FTD), semantic dementia, and progressive nonfluent aphasia, with FTD being the most prevalent. FTD is characterized predominantly by character change and disordered social conduct. A variety of pathologies may underlie these syndromes, yet it is the location of the pathology rather than the type that dictates the clinical features of the disease. Several medications have been investigated to measure efficacy of treatment in FTD, often with mixed results. The authors review these findings and comment on future directions.
Kaye
Edward D
ED
Baycrest, Kunin-Lunenfeld Applied Research Unit, Toronto, Ontario, Canada. tkaye@klaru-baycrest.on.ca
Petrovic-Poljak
Ana
A
Verhoeff
Nicolaas P L G
NP
Freedman
Morris
M
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001921:Brain / Q000201:enzymology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D057180:Frontotemporal Dementia / Q000188:drug therapy* / Q000201:enzymology; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D011985:Receptors, Serotonin / Q000378:metabolism; D000068836:Rivastigmine; D012642:Selegiline / Q000627:therapeutic use*
D000928:Antidepressive Agents; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D011985:Receptors, Serotonin; D005702:Galantamine; D012642:Selegiline; D002795:Choline O-Acetyltransferase; D000068836:Rivastigmine; D004298:Dopamine